SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, affirms that, based on the strength of the positive interim results from its Phase 2 CAReS trial of ART27.13 for cancer anorexia-cachexia syndrome (CACS) and the strong interest expressed by multiple pharmaceutical companies a ...

Core Insights - Artelo Biosciences, Inc. announced interim results from its Phase 2 Cancer Appetite Recovery Study (CAReS) trial for ART27.13, showing significant improvements in weight gain and lean body mass in cancer patients suffering from anorexia-cachexia syndrome (CACS) [2][4][8] - The study demonstrated a mean weight gain of +6.4% at 12 weeks for ART27.13 compared to a mean weight loss of -5.4% in the placebo group, indicating a compelling drug effect [5][7] - ART27.13 was well tolerated, with adverse events primarily mild or moderate, aligning with previous safety findings [6][8] Company Overview - Artelo Biosciences is focused on developing treatments for cancer, pain, and other conditions by modulating lipid-signaling pathways [2][12] - The company is accelerating its licensing strategy based on the strength of the interim data and a recently allowed patent application for its commercial formulation [8][12] - ART27.13 is a novel agent targeting peripheral cannabinoid receptors, with potential benefits in improving appetite, weight, and quality of life for cancer patients [9][11] Clinical Study Details - The CAReS trial is a Phase 1/2 randomized, placebo-controlled study evaluating ART27.13 in patients with cancer-related anorexia and weight loss [10] - The Phase 2 portion aims to assess the drug's effectiveness in increasing lean body mass and improving appetite compared to placebo [10] - Interim analysis included 18 evaluable patients, primarily with lung and gastrointestinal cancers, showing significant weight gain and lean body mass improvements [5][6] Market Context - CACS affects up to 80% of cancer patients, representing a significant unmet medical need with a market potential exceeding $3 billion [11] - Currently, there are no FDA-approved treatments for CACS, highlighting the importance of ART27.13's development [11]